Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies

NCT02730299 is registered in ClinicalTrials.gov with Gamida Cell ltd as lead sponsor.

NCT NCT02730299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Lead sponsor
Gamida Cell ltd
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2016
Completion date
February 7, 2025
Enrollment
125 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), chronic myelogenous leukemia (cml), hematological malignancies, lymphoma, myelodysplastic syndrome (mds)